Merck & Co., Inc. (NYSE:MRK – Get Free Report) and ABVC BioPharma (NASDAQ:ABVC – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.
Valuation and Earnings
This table compares Merck & Co., Inc. and ABVC BioPharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Merck & Co., Inc. | $65.01 billion | 5.53 | $18.25 billion | $1.25 | 116.53 |
| ABVC BioPharma | $510,000.00 | 48.80 | -$7.91 million | ($0.30) | -3.11 |
Merck & Co., Inc. has higher revenue and earnings than ABVC BioPharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Merck & Co., Inc. and ABVC BioPharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Merck & Co., Inc. | 4.77% | 16.73% | 6.13% |
| ABVC BioPharma | N/A | -47.68% | -30.97% |
Insider and Institutional Ownership
76.1% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 0.2% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Merck & Co., Inc. has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Merck & Co., Inc. and ABVC BioPharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Merck & Co., Inc. | 0 | 10 | 17 | 0 | 2.63 |
| ABVC BioPharma | 1 | 0 | 0 | 0 | 1.00 |
Merck & Co., Inc. currently has a consensus target price of $151.92, suggesting a potential upside of 4.30%. Given Merck & Co., Inc.’s stronger consensus rating and higher probable upside, research analysts clearly believe Merck & Co., Inc. is more favorable than ABVC BioPharma.
Summary
Merck & Co., Inc. beats ABVC BioPharma on 10 of the 13 factors compared between the two stocks.
About Merck & Co., Inc.
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.
About ABVC BioPharma
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
